Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12232195 | 0.92 | ALDH1A1 (0.52) | ALDH1A1KMT2APOLBRAB9AHPGD | |
| SCHEMBL1126706 | 0.86 | ALDH1A1 (0.62) | ALDH1A1KMT2ARAB9AHPGDNPC1 | |
| SCHEMBL4460442 | 0.84 | ALDH1A1 (0.75) | ALDH1A1KMT2APOLBRAB9AHPGD | |
| SCHEMBL29757646 | 0.81 | RAB9A (0.56) | ALDH1A1KMT2ARAB9AHPGDNPC1 | |
| SCHEMBL1126748 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KMT2APOLBRAB9AHPGD | |
| SCHEMBL24584793 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KMT2ARAB9AHPGDNPC1 | |
| SCHEMBL1127449 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KMT2APOLBRAB9AHPGD | |
| SCHEMBL4457671 | 0.79 | ALDH1A1 (0.70) | ALDH1A1KMT2APOLBRAB9AHPGD | |
| SCHEMBL1126493 | 0.79 | MAPT (0.53) | ALDH1A1KMT2ARAB9AHPGDNPC1 | |
| SCHEMBL4465025 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KMT2APOLBRAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003035614-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | claimed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| WO-2008076278-A2 | METHODS OF CANCER TREATMENT WITH IGF1R INHIBITORS | SCHERING CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2003035614-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | ALDH1A1 1627/4885KMT2A 576/4885POLB 2278/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | ALDH1A1 484/4885KMT2A 2332/4885POLB 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.